samedan logo
 
 
 
spacer
home > ebr > spring 2008 > australian research excellence
PUBLICATIONS
European Biopharmaceutical Review

Australian Research Excellence

Australian research is attracting attention from European biotechnology companies, thanks to its rapid improvement and growth. Nicola Watkinson of the Australian Government explains why the future’s bright for the Australian biotechnology industry

In a recent report, Ernst & Young note that the global biotech industry achieved a 14 per cent overall growth rate in 2006 to exceed US$73 billion in revenues (1). If the double-digit growth continues over the next few years, then the biotech industry is set to become a US$100 billion industry by the end of this decade (2). This growth, driven primarily by expansion in the US and European biotech industries, is flowing to Australian shores as international companies are increasingly choosing to do business with innovative Australian biotech players. Australia generated more than 72 per cent of the total biotech revenue in the Asia-Pacific in 2006 (3).

AUSTRALIAN BIOTECH – AN INDUSTRY OVERVIEW

Australia is the number one biotechnology location in the Asia-Pacific (4). Recent developments in Australia’s biotech industry that have spiked the interest of the global biotech community include its increased maturity and strong growth. Since 2002, the number of core biotechnology companies in Australia has more than doubled to 470 (5). This rapid growth has created a greater critical mass, bringing depth to the domestic market, strengthening market potential and offering global companies even more partnering opportunities with Australian companies. A significant development in the Australian biotech industry was the 2007 merger of therapeutic companies EvoGenix and Peptech Limited to form Arana Therapeutics, now one of Australia’s biggest biotechnology companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nicola Watkinson is the Australian Government’s Senior Investment Commissioner for Europe. With a comprehensive knowledge of Australia’s biotechnology capabilities, she also has several years experience in working closely with European businesses to help identify partnership opportunities with Australian companies. Nicola manages offices in France, the UK and Germany and has been living in Frankfurt since 2002.
spacer
Nicola Watkinson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Healthcare Best-in-class syringe components for high safety and functionality

We are pleased to announce that Datwyler has become a strategic partner for the supply of the rubber plungers for the Retrago syringes. This is the result of intensive team work to develop the customized design of four different plungers, provide samples for trials and prepare commercial production within shortest time lines possible.  
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement